List of those eligible from here:www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAttachment.aspx?Attachment_id=103862
I recommend going to the document and reading Appendix 1 as the list is clearly set out there!
Down’s syndrome
All patients with Down’s syndrome
Sickle cell disease
All patients with a diagnosis of sickle cell disease
Patients with a solid cancer
• Active metastatic cancer and active solid cancers (at any stage)
• All patients receiving chemotherapy within the last 3 months
• Patients receiving group B or C chemotherapy 3-12 months prior
• Patients receiving radiotherapy within the last 6 months
Patients with a haematologic malignancy
• Allogeneic haematopoietic stem cell transplant (HSCT) recipients in the last 12 months or active graft vs host disease (GVHD) regardless of time from transplant
• Autologous HSCT recipients in the last 12 months
• Individuals with haematological malignancies who
have
o received chimaeric antigen receptor (CAR)-T
cell therapy in the last 24 months, or
o anti-CD20 monoclonal antibody therapy in
the last 12 months
• Individuals with chronic B-cell lymphoproliferative
disorders receiving systemic treatment or
radiotherapy within the last 3 months
• Individuals with chronic B-cell lymphoproliferative
disorders with hypogammaglobulinaemia or
reduced peripheral B cell counts
• Individuals with acute leukaemias and clinically
aggressive lymphomas who are receiving chemotherapy or within 3 months of completion at the time of vaccination
7 For paediatric/adolescent patients (aged 12-17 years inclusive), paediatric multi-disciplinary team (MDT) assessment should be used to determine clinical capacity to benefit from the treatment
7
• Individuals with haematological malignancies who have received anti-CD38 monoclonal antibody or B- cell maturation agent (BCMA) targeted therapy in the last 6 months
• Individuals with chronic B-cell lymphoproliferative disorders not otherwise described above
Patients with renal disease
• Renal transplant recipients (including those with failed transplants within the past 12 months), particularly those who:
o Received B cell depleting therapy within the past 12 months (including alemtuzumab, rituximab [anti-CD20], anti-thymocyte globulin)
o Have an additional substantial risk factor which would in isolation make them eligible for nMABs or oral antivirals
o Not been vaccinated prior to transplantation
• Non-transplant patients who have received a
comparable level of immunosuppression
• Patients with chronic kidney stage (CKD) 4 or 5 (an
eGFR less than 30 ml/min/1.73m2) without immunosuppression
Patients with liver disease
• Patients with cirrhosis Child’s-Pugh class B and C (decompensated liver disease).
• Patients with a liver transplant
• Liver patients on immune suppressive therapy
(including patients with and without liver cirrhosis)
• Patients with cirrhosis Child’s-Pugh class A who are
not on immune suppressive therapy (compensated liver disease)
Patients with immune-mediated inflammatory disorders (IMID)
• IMID treated with rituximab or other B cell depleting therapy in the last 12 months
• IMID with active/unstable disease on corticosteroids, cyclophosphamide, tacrolimus, cyclosporin or mycophenolate.
• IMID with stable disease on either corticosteroids, cyclophosphamide, tacrolimus, cyclosporin or mycophenolate.
• IMID patients with active/unstable disease including those on biological monotherapy and on combination biologicals with thiopurine or methotrexate
Primary immune deficiencies
• Common variable immunodeficiency (CVID)
• Undefined primary antibody deficiency on
immunoglobulin (or eligible for Ig)
• Hyper-IgM syndromes
• Good’s syndrome (thymoma plus B-cell deficiency)
• Severe Combined Immunodeficiency (SCID)
8
• Autoimmune polyglandular syndromes/autoimmune polyendocrinopathy, candidiasis, ectodermal dystrophy (APECED syndrome)
• Primary immunodeficiency associated with impaired type I interferon signalling
• X-linked agammaglobulinaemia (and other primary agammaglobulinaemias)
HIV/AIDS
• Patients with high levels of immune suppression, have uncontrolled/untreated HIV (high viral load) or present acutely with an AIDS defining diagnosis
• On treatment for HIV with CD4 350 cells/mm3 and additional risk factors (e.g. age, diabetes, obesity, cardiovascular, liver or renal disease, homeless, those with alcohol-dependence)
Solid organ transplant recipients
All recipients of solid organ transplants not otherwise specified above
Rare neurological conditions
• Multiple sclerosis
• Motor neurone disease
• Myasthenia gravis
• Huntington’s disease